|
|
 |
TRIETHYL CITRATE Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
TAVALISSE Drug Profile, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
TRAGACANTH Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
TRIACETIN Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|